This study is in progress, not accepting new patients
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Summary
- Eligibility
- for people ages 60-85 (full criteria)
- Location
- at UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Julio Rojas-Martinez (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Julio Rojas-Martinez (ucsf)
Associate Professor, Neurology, School of Medicine. Authored (or co-authored) 125 research publications. Research interests: Clinical trials · fluid biomarkers · non-pharmacological management · Alzheimer's disease · PSP · FTD
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Donanemab (LY3002813) in Participants with Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
- ID
- NCT04437511
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 1736 people participating
- Last Updated